Posted Jan. 9, 2012 at 3:59 p.m.
BioCryst
Research Triangle Park, N.C. — BioCryst is studying the compound called BCX4208 as an adjunct therapy for patients using the gout drug allopurinol. Allopurinol reduces the uric acid production that leads to inflammation and joint pain experienced by gout patients.Copyright 2013 WRAL Tech Wire. All rights reserved.
Durham firm's gout treatment shows promise in clinical trial
Post a comment
Print this blog postE-mail blog post
Share
BioCryst
Research Triangle Park, N.C. — BioCryst is studying the compound called BCX4208 as an adjunct therapy for patients using the gout drug allopurinol. Allopurinol reduces the uric acid production that leads to inflammation and joint pain experienced by gout patients.Copyright 2013 WRAL Tech Wire. All rights reserved.
Log in or upgrade to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
NC Biotech Center braces for worst as Senate slashes budget, too- ArchiveSocial, a new Durham success story, brings home international award
- Durham's high-tech infrastructure, talent lure Virginia company
- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows